Therapeutic options for Acinetobacter baumannii infections: an update

Bibliography

• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-2
   PubMed Web of Science ®Google Scholar
• Espinal P, Roca I, Vila J. Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol 2011;6:495-511
   PubMedGoogle Scholar
• Nemec A, Krizova L, Maixnerova M, Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol 2011;162:393-404
   PubMed Web of Science ®Google Scholar
• Espinal P, Seifert H, Dijkshoorn L, Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS. Clin Microbiol Infect 2011; doi:10.1111/j.469-0691.2011.036960.x
   PubMedGoogle Scholar
• Magiorakos AP, Srinivasan A, Carey RB, Multi-drug resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81
   PubMed Web of Science ®Google Scholar
• Espinal P, Marti S, Vila J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J Hosp Infect 2012;80:56-60
   PubMed Web of Science ®Google Scholar
• Viana GF, dos Santos Saalfeld SM, Garcia LB, Evolution of antimicrobial resistance of Acinetobacter baumannii in a university hospital. Lett Appl Microbiol 2011;53:374-8
   PubMed Web of Science ®Google Scholar
• Reddy T, Chopra T, Marchaim D, Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a Metropolitan Detroit health system. Antimicrob Agents Chemother 2010;54:2235-8
   PubMed Web of Science ®Google Scholar
• Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agnets 2012;39:105-14
   PubMed Web of Science ®Google Scholar
• Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among Gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the tigecycline evaluation and surveillance trial. Clin Ther 2011;34:124-37
   PubMedGoogle Scholar
• Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J Chemother 2011;23:13-16
   PubMed Web of Science ®Google Scholar
• Park YK, Jung SI, Park KH, Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 2009;64:43-51
   PubMed Web of Science ®Google Scholar
• Rolain JM, Roch A, Castanier M, Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis 2011;204:1146-7
   PubMedGoogle Scholar
• Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline & colistin resistant Acinetobacter baumannii in patients with complicated urinary tract infections in north India. Indian J Med Res 2011;133:681-4
   PubMed Web of Science ®Google Scholar
• Roca I, Espinal P, Vila-Farres X, The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug resistant menace. Front Microbiol 2012;3:148
   PubMed Web of Science ®Google Scholar
• Potron A, Munoz-Price LS, Nordmann P, Genetic features of CTX-M-15-producing Acinetobacter baumannii from Haiti. Antimicrob Agents Chemother 2011;55:5946-8
   PubMedGoogle Scholar
• Shakil S, Khan AU. Detection of CTX-M-15-producing and carbapenem-resistant Acinetobacter baumannii strains from urine from an Indian hospital. J Chemother 2010;22:324-7
   PubMed Web of Science ®Google Scholar
• Robledo IE, Aquino EE, Sante MI, Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother 2010;54:1354-7
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA. Updated functional classification of ß-lactamases. Antimicrob Agents Chemother 2010;54:969-76
   PubMed Web of Science ®Google Scholar
• Kaase M, Nordmann P, Wichelhaus TA, NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother 2011;66:1260-2
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou Z, Jiang Y, Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother 2011;66:1255-9
   PubMed Web of Science ®Google Scholar
• Pfeifer Y, Wilharm G, Zander E, Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. J Antimicrob Chemother 2011;66:1998-2001
   PubMed Web of Science ®Google Scholar
• Espinal P, Fugazza G, Lopez Y, Dissemination of the NDM-2-producing Acinetobacter baumannii clone in an Israeli Rehabilitation Center. Antimicrob Agents Chemother 2011;55:5396-8
   PubMed Web of Science ®Google Scholar
• Mugnier PD, Poirel L, Naas T, Worlwide dissemination of the blaOXA23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010;16:35-40
   PubMed Web of Science ®Google Scholar
• Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007;59:1210-15
   PubMed Web of Science ®Google Scholar
• Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001;45:3375-80
   PubMed Web of Science ®Google Scholar
• Yu YS, Zhou H, Yang Q, Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenem-resistant Acinetobacter baumannii isolates in China. J Antimicrob Chemother 2007;60:454-5
   PubMed Web of Science ®Google Scholar
• Fabrega A, Madurga S, Giralt E, Mechanism of action of and resistance to quinolones. Microb Biotechnol 2009;2:40-61
   PubMed Web of Science ®Google Scholar
• Damier-Piolle L, Magnet S, Bremont S, AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008;52:557-62
   PubMed Web of Science ®Google Scholar
• Liang W, Liu XF, Huang J, Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis 2011;11:109
   Google Scholar
• Morfin-Otero R, Dowzicky MJ. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the tigecycline evaluation and surveillance trial, 2004 to 2009. Clin Ther 2012;34:101-12
   PubMed Web of Science ®Google Scholar
• Marti S, Fernandez-Cuenca F, Pascual A, Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates. Enferm Infecc Microbiol Clin 2006;24:77-80
   PubMed Web of Science ®Google Scholar
• Huys G, Cnockaert M, Vaneechoutte M, Distribution of tetracycline resistance genes in genotypically related and unrelated multiresistant Acinetobacter baumannii strains from different European hospitals. Res Microbiol 2005;156:348-55
   PubMedGoogle Scholar
• Giannouli M, Di Popolo A, Durante-Mangoni E, Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy. Int J Antimicrob Agents 2012;39:58-63
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41
   PubMed Web of Science ®Google Scholar
• Adams MD, Nickel GC, Bajaksouzian S, Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009;53:3628-34
   PubMed Web of Science ®Google Scholar
• Arroyo LA, Herrera CM, Fernandez L, The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother 2011;55:3743-51
   PubMed Web of Science ®Google Scholar
• Beceiro A, Llobet E, Aranda J, Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011;55:3370-9
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Harrison P, Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;54:4971-7
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Adler B, Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55:3022-4
   PubMed Web of Science ®Google Scholar
• Fernandez-Reyes M, Rodriguez-Falcon M, Chiva C, The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 2009;9:1632-45
   PubMed Web of Science ®Google Scholar
• Valencia-Martin R, Arroyo LA, Conde M, Nosocomial outbreak of pandrug-resistant Acinetobacter baumannii in a tertiary-level university hospital. Infect Control Hosp Epidemiol 2009;30:257-63
   PubMedGoogle Scholar
• Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9
   PubMed Web of Science ®Google Scholar
• Sunenshine HR, Wright MO, Maragakis LL, Multidrug resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13:97-103
   PubMed Web of Science ®Google Scholar
• Fagon JY, Chastre J, Domart Y, Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996;23:538-42
   PubMed Web of Science ®Google Scholar
• Garnacho J, Sole-Violan J, Sa-Borges M, Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003;31:2478-82
   PubMed Web of Science ®Google Scholar
• Chen SF, Chang WN, Lu CH, Adult Acinetobacter meningitis and its comparison with non-Acinetobacter gram-negative bacterial meningitis. Acta Neurol Taiwan 2005;14:131-7
   PubMedGoogle Scholar
• Jimenez-Mejias ME, Pachon J, Becerril B, Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997;24:932-5
   PubMed Web of Science ®Google Scholar
• Cisneros JM, Reyes MJ, Pachon J, Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026-32
   PubMed Web of Science ®Google Scholar
• Kuo LC, Lai CC, Liao CH, Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and prognosis. Clin Microbiol Infect 2007;13:196-8
   PubMed Web of Science ®Google Scholar
• Joung MK, Kwon KT, Kang CI, Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 2010;61:212-18
   PubMedGoogle Scholar
• Erbay A, Idil A, Gozel MG, Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009;34:575-9
   PubMed Web of Science ®Google Scholar
• Esterly JS, Griffith M, QI C, Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream Infections. Antimicrob Agents Chemother 2011;55:4844-9
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Int Care Med 2005;31:649-55
   PubMed Web of Science ®Google Scholar
• Lee YT, Kuo SC, Yang SP, Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012;55(2):209-15
   PubMed Web of Science ®Google Scholar
• Vila J, Pachon J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008;9:587-99
   PubMed Web of Science ®Google Scholar
• Corbella X, Ariza J, Ardanuy C, Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J. Antimicrob Chemother 1998;42:793-802
   PubMed Web of Science ®Google Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432-6
   PubMed Web of Science ®Google Scholar
• Levin AS, Levy CE, Manrique AE, Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003;21:58-62
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369-75
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuenca F, Pascual A, Ribera A, Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales espanoles. Estudio multicentrico nacional: proyecto GEIH-Ab 2000. Enferm Infecc Microbiol Clin 2004;22:267-71
   PubMedGoogle Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007;39:38-43
   PubMed Web of Science ®Google Scholar
• Rodriguez-Hernandez MJ, Cuberos L, Pichardo C, Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 2001;47:479-82
   PubMed Web of Science ®Google Scholar
• Bantar C, Canigia LF, Berger MA, Pharmacodynamic assessment of amoxicillin-sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model. Braz J Infect Dis 2009;13:348-52
   PubMedGoogle Scholar
• Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007;57:419-22
   PubMed Web of Science ®Google Scholar
• Owen RJ, LI J, Nation RL, In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59:473-7
   PubMed Web of Science ®Google Scholar
• Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008;52:351-2
   PubMed Web of Science ®Google Scholar
• Rodriguez CH, Barberis C, Nastro M, Impact of heteroresistance to colistin in meningitis caused by Acinetobacter baumannii. J Infect 2012;64:119-21
   PubMedGoogle Scholar
• Garnacho-Montero J, Ortiz-Leyva C. Jimenez-Jimenez, FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-18
   PubMed Web of Science ®Google Scholar
• Kallel H, Hergafi L, Bahloul M, Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Int Care Med 2007;33:1162-7
   PubMed Web of Science ®Google Scholar
• Gounden R, Bamford C, Van Zyl-Smit R, Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009;9:26
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67(7):1607-15
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
   PubMed Web of Science ®Google Scholar
• David MD, Gill MJ. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother 2008;61:962-4
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94
   PubMed Web of Science ®Google Scholar
• Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002;21:212-14
   PubMed Web of Science ®Google Scholar
• De Pascale G, Pompucci A, Maviglia R, Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intrathecal and intravenous colistin. Minerva Anestesiol 2010;76:957-60
   PubMed Web of Science ®Google Scholar
• Dalgic N, Ceylan Y, Sancar M, Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. Ann. Trop Paediatr 2009;29:141-7
   PubMed Web of Science ®Google Scholar
• Ng J, Gosbell IB, Kelly JA, Cure of multiresistant Acinetobacter baumannii central nervous infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006;58:1078-81
   PubMed Web of Science ®Google Scholar
• Cascio A, Conti A, Sinardi L, Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis 2010;14:e572-9
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infect 2010;16:888-94
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hartman BJ, Kaplan SL, Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84
   PubMed Web of Science ®Google Scholar
• Lin CC, Liu TC, Kuo CF, Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010;43:323-31
   PubMedGoogle Scholar
• Molina J, Cordero E, Pachon J. New information about the Polymyxin/Colistin class of antibiotics. Expert Opin Pharmacother 2009;10:2811-28
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Antimicrobial activity of tigecycline (GAR-936) against multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:4479-81
   PubMed Web of Science ®Google Scholar
• Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial. J Infect 2007;55:49-57
   PubMed Web of Science ®Google Scholar
• Betriu C, Rodriguez-Avial I, Gomez M, and the Spanish Tigecycline Group. Antimicrobial activity of tigecycline against clinical isolates of Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 2006;56:437-44
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005 – 2009). Diagn Microbiol Infect Dis 2010;68:307-11
   PubMed Web of Science ®Google Scholar
• Casal M, Rodriguez F, Johnson B, Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J Antimicrob Chemother 2009;64:69-72
   PubMed Web of Science ®Google Scholar
• Pillar CM, Draghi DC, Dowzicky MJ, In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 2008;46:2862-7
   PubMedGoogle Scholar
• Peleg AY, Potoski BA, Rea R, Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31
   PubMed Web of Science ®Google Scholar
• Reid GE, Grim SA, Aldeza CA, Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198-201
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008;62:45-55
   PubMed Web of Science ®Google Scholar
• Vasilev K, Reshedko G, Orasan R, A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii, and Klebsiella pneumoniae. J Antimicrob Chemother 2008;62(Suppl 1):i29-40
   PubMedGoogle Scholar
• Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775-80
   PubMed Web of Science ®Google Scholar
• Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 2010;25:343-8
   PubMedGoogle Scholar
• Guner R, Hasanoglu I, Keske S, Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 2011;39:515-18
   PubMed Web of Science ®Google Scholar
• Ye JJ, Lin HS, Kuo AJ, The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 2011;63:351-61
   PubMed Web of Science ®Google Scholar
• Curcio D, Fernandez F, Vergara J, Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009;21:58-62
   PubMed Web of Science ®Google Scholar
• Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009;47:1613
   PubMed Web of Science ®Google Scholar
• Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J Clin Microbiol 2008;46:1892-3
   PubMed Web of Science ®Google Scholar
• Tutuncu EE, Kuscu F, Gurbuz Y, Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis 2010;14(Suppl 3):e224-6
   PubMed Web of Science ®Google Scholar
• Ray L, Levasseur K, Nicolau DP, Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother 2010;44:582-6
   PubMed Web of Science ®Google Scholar
• Lengerke C, Haap M, Mayer F, Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges. Antimicrob Agents Chemother 2011;55:449-50
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm224383.htm [Accessed 30 August 2011]
   Google Scholar
• Gounden R, Bamford C, van Zyl-Smit R, Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009;9:26
   PubMed Web of Science ®Google Scholar
• Rodriguez-Hernandez MJ, Pachon J, Pichardo C, Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 2000;45:493-501
   PubMedGoogle Scholar
• Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A, Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005;11:319-25
   PubMed Web of Science ®Google Scholar
• Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009;33:290-1
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R, Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:1165-72
   PubMed Web of Science ®Google Scholar
• Lee NY, Wang CL, Chuang YC, Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 2007;27:1506-11
   PubMed Web of Science ®Google Scholar
• Wolff M, Joly-Guillou ML, Farinotti R, In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999;43:1406-11
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X, Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946-52
   PubMed Web of Science ®Google Scholar
• Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Colistin offers prolonged survival in experimental infection by multiresistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007;29:51-5
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Lee J, Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 2009;33:33-9
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Fernandez-Cuenca F, Docobo-Perez F, Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 2006;58:689-92
   PubMed Web of Science ®Google Scholar
• Saballs M, Pujol M, Tubau F, Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006;58:697-700
   PubMed Web of Science ®Google Scholar
• Gleeson T, Petersen K, Mascola J. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. J Antimicrob Chemother 2005;56:602-3
   PubMedGoogle Scholar
• Mellon G, Clec'h C, Picard B, Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother 2012; Epub ahead of print
   Google Scholar
• Sacar S, Turgut H, Cenger DH, Successful treatment of multidrug resistant Acinetobacter baumannii meningitis. J Infect Dev Ctries 2007;1:342-4
   PubMed Web of Science ®Google Scholar
• Motaouakkil S, Charra B, Hachimi A, Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006;53:274-8
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Owen RJ, Antibiograms of multi-drug clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007;45:594-8
   PubMed Web of Science ®Google Scholar
• Bassetti M, Repetto E, Righi E, Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-20
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Chinello P, Proietti MF, Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682-3
   PubMed Web of Science ®Google Scholar
• Shields RK, Kwak EJ, Potoski BA, High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 2011;70:246-52
   PubMed Web of Science ®Google Scholar
• Biancofiore G, Tascini C, Bisa M, Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol 2007;73:181-5
   PubMed Web of Science ®Google Scholar
• Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011;66:1047-51
   PubMed Web of Science ®Google Scholar
• Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:5316-22
   PubMed Web of Science ®Google Scholar
• Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 2011;55:3534-7
   PubMed Web of Science ®Google Scholar
• Giacometti A, Cirioni O, Del Prete MS, Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2000;46:807-10
   PubMedGoogle Scholar
• Ge Y, MacDonald DL, Holroyd KJ, In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 1999;43:782-8
   PubMed Web of Science ®Google Scholar
• Conlon JM, Ahmed E, Condamine E. Antimicrobial properties of brevinin-2-related peptide and its analogs: efficacy against multidrug-resistant Acinetobacter baumannii. Chem Biol Drug Des 2009;74:488-93
   PubMed Web of Science ®Google Scholar
• Conlon JM, Sonnevend A, Pal T, Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group. Int J Antimicrob Agents 2012;39:317-20
   PubMed Web of Science ®Google Scholar
• Conlon JM, Mechkarska M, Arafat K, Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria. J Pept Sci 2012;18:270-5
   PubMed Web of Science ®Google Scholar
• Vila-Farres X, Garciade la Maria C, Lopez-Rojas R, In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 2012;18:383-7
   PubMed Web of Science ®Google Scholar
• Cirioni O, Silvestri C, Ghiselli R, Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. Crit Care Med 2009;37:1403-7
   PubMed Web of Science ®Google Scholar
• Rodriguez-Hernandez MJ, Saugar J, Docobo-Perez F, Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2006;58:95-100
   PubMed Web of Science ®Google Scholar
• Braunstein A, Papo N, Shai Y. In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother 2004;48:3127-9
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, Docobo-Perez F, Pachon-Ibanez ME, Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 2011;30:1391-8
   PubMed Web of Science ®Google Scholar
• Ostorhazi E, Rozgonyi F, Szabo D, Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections. Biopolymers 2011;96:126-9
   PubMed Web of Science ®Google Scholar
• Ostorhazi E, Rozgonyi F, Sztodola A, Preclinical advantages of intramuscularly administered peptide A3-APO overexisting therapies in Acinetobacter baumannii wound infections. J Antimicrob Chemother 2010;65:2416-22
   PubMed Web of Science ®Google Scholar
• Vila J, Sanchez-Cespedes J, Sierra JM, Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria. Int J Antimicrob Agents 2006;28:19-24
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, Sanchez-Cespedes J, Docobo-Perez F, Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. Int J Antimicrob Agents 2011;38:355-9
   PubMedGoogle Scholar
• Tan Q, Ogawa AM, Raghoobar SL, Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Bioorg Med Chem Lett 2011;21:4363-5
   PubMedGoogle Scholar
• Higgins PG, Stefanik D, Page MG, In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 2012;67:1167-9
   PubMed Web of Science ®Google Scholar
• Mihu MR, Sandkovsky U, Han G, The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections. Virulence 2010;1:62-7
   PubMed Web of Science ®Google Scholar
• Ghosh S, Patil S, Ahire M, Synthesis of silver nanoparticles using Dioscorea bulbifera tuber extract and evaluation of its synergistic potential in combination with antimicrobial agents. Int J Nanomedicine 2012;7:483-96
   PubMed Web of Science ®Google Scholar
• Dai T, Tegos GP, Lu Z, Photodynamic therapy for Acinetobacter baumannii burn infections in mice. Antimicrob Agents Chemother 2009;53:3929-34
   PubMed Web of Science ®Google Scholar
• Vila J, Pachon J. Acinetobacter baumannii resistant to everything, what should we do? Clin Microbiol Infect 2011;17:955-6
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Garcia L, Ramirez E, Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive ‘‘bundle'' approach. Am J Infect Control 2009;37:715-22
   PubMed Web of Science ®Google Scholar